Chapter 7

This is a listing of all citations in this chapter.

61

Gaetano A. Lanza et al., “Inflammation-Related Effects of Adjuvant Influenza A Vaccination on Platelet Activation and Cardiac Autonomic Function,” Journal of Internal Medicine, 269 no.1 (2011): 118–125. doi:10.1111/j.1365-2796.2010.02285.x.

62

Elizabeth Miller et al., “Risk of Narcolepsy in Children and Young People Receiving AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine: Retrospective Analysis,” BMJ 346, (2013): f794, doi:10.1136/bmj.f794.

63

Attila Szakács, Niklas Darin and Tove Hallböök, “Increased Childhood Incidence of Narcolepsy in Western Sweden After H1N1 Influenza Vaccination,” Neurology 80, no. 14 (2013): 1315-1321, doi:10.1212/WNL.0b013e31828ab26f.

64

Markku Partinen et al., “Increased Incidence and Clinical Picture of Childhood Narcolepsy Following the 2009 H1N1 Pandemic Vaccination Campaign in Finland,” PLoS ONE 7, no. 3 (2012): e33723, doi:10.1371/journal.pone.0033723.

65

Matthew Wise, et al., “Guillain-Barre Syndrome During the 2009-2010 H1N1 Influenza Vaccination Campaign: Population-Based Surveillance Among 45 Million Americans,” American Journal of Epidemiology 175, no. 11 (2012): 1110–1119, doi:10.1093/aje/kws196.

66

Jerome I. Tokars et al., “The Risk of Guillain-Barré Syndrome Associated with Influenza A (H1N1) 2009 Monovalent Vaccine and 2009-2010 Seasonal Influenza Vaccines: Results from Self-Controlled Analyses,” Pharmacoepidemiology and Drug Safety 21, no. 5 (2012): 546-552, doi:10.1002/pds.3220.

67

Daniel A. Salmon et al., “Association Between Guillain-Barré Syndrome and Influenza A (H1N1) 2009 Monovalent Inactivated Vaccines in the USA: A Meta-Analysis,” Lancet 381, no. 9876 (2013): 1461-1468, doi:10.1016/S0140-6736(12)62189-8.

68

Elizabeth Miller et al., “Risk of Narcolepsy in Children and Young People Receiving AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine: Retrospective Analysis,” BMJ 346, (2013): f794, doi:10.1136/bmj.f794.

69

Attila Szakács, Niklas Darin and Tove Hallböök, “Increased Childhood Incidence of Narcolepsy in Western Sweden After H1N1 Influenza Vaccination,” Neurology 80, no. 14 (2013): 1315-1321, doi:10.1212/WNL.0b013e31828ab26f.

70

Markku Partinen et al., “Increased Incidence and Clinical Picture of Childhood Narcolepsy Following the 2009 H1N1 Pandemic Vaccination Campaign in Finland,” PLoS ONE 7, no. 3 (2012): e33723, doi:10.1371/journal.pone.0033723.

71

Carola Bardage et al., “Neurological and Autoimmune Disorders After Vaccination Against Pandemic Influenza A (H1N1) with a Monovalent Adjuvanted Vaccine: Population Based Cohort Study in Stockholm, Sweden,” BMJ 343, (2011): d5956, doi:10.1136/bmj.d5956.

72

Carola Bardage et al., “Neurological and Autoimmune Disorders After Vaccination Against Pandemic Influenza A (H1N1) with a Monovalent Adjuvanted Vaccine: Population Based Cohort Study in Stockholm, Sweden,” BMJ 343, (2011): d5956, doi:10.1136/bmj.d5956.

73

Carola Bardage et al., “Neurological and Autoimmune Disorders After Vaccination Against Pandemic Influenza A (H1N1) with a Monovalent Adjuvanted Vaccine: Population Based Cohort Study in Stockholm, Sweden,” BMJ 343, (2011): d5956, doi:10.1136/bmj.d5956.

74

Alexa Dierig et al., “Epidemiology of Respiratory Viral Infections in Children Enrolled in a Study of Influenza Vaccine Effectiveness,” Influenza and Other Respiratory Viruses 8, no. 3 (2014): 293–301, doi:10.1111/irv.12229.